Oral substitution treatment of injecting opioid users for prevention of HIV infection

Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R (2011)
The Cochrane database of systematic reviews (8).

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ; ;
Abstract
Background Injecting drug users are vulnerable to infection with Human Immunodeficiency Virus (HIV) and other blood borne viruses as a result of collective use of injecting equipment as well as sexual behaviour Objectives To assess the effect of oral substitution treatment for opioid dependent injecting drug users on risk behaviours and rates of HIV infections\ Search strategy We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and PsycINFO toMay 2011. We also searched reference lists of articles, reviews and conference abstracts Selection criteria Studies were required to consider the incidence of risk behaviours, or the incidence of HIV infection related to substitution treatment of opioid dependence. All types of original studies were considered. Two authors independently assessed each study for inclusion Data collection and analysis Two authors independently extracted key information from each of the included studies. Any differences were resolved by discussion or by referral to a third author. Main results Thirty-eight studies, involving some 12,400 participants, were included. The majority were descriptive studies, or randomisation processes did not relate to the data extracted, and most studies were judged to be at high risk of bias. Studies consistently show that oral substitution treatment for opioid-dependent injecting drug users with methadone or buprenorphine is associated with statistically significant reductions in illicit opioid use, injecting use and sharing of injecting equipment. It is also associated with reductions in the proportion of injecting drug users reporting multiple sex partners or exchanges of sex for drugs or money, but has little effect on condom use. It appears that the reductions in risk behaviours related to drug use do translate into reductions in cases of HIV infection. However, because of the high risk of bias and variability in several aspects of the studies, combined totals were not calculated. Authors' conclusions Oral substitution treatment for injecting opioid users reduces drug-related behaviours with a high risk of HIV transmission, but has less effect on sex-related risk behaviours. The lack of data from randomised controlled studies limits the strength of the evidence presented in this review.
Publishing Year
ISSN
PUB-ID

Cite this

Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. The Cochrane database of systematic reviews. 2011;(8).
Gowing, L., Farrell, M. F., Bornemann, R., Sullivan, L. E., & Ali, R. (2011). Oral substitution treatment of injecting opioid users for prevention of HIV infection. The Cochrane database of systematic reviews(8).
Gowing, L., Farrell, M. F., Bornemann, R., Sullivan, L. E., and Ali, R. (2011). Oral substitution treatment of injecting opioid users for prevention of HIV infection. The Cochrane database of systematic reviews.
Gowing, L., et al., 2011. Oral substitution treatment of injecting opioid users for prevention of HIV infection. The Cochrane database of systematic reviews, (8).
L. Gowing, et al., “Oral substitution treatment of injecting opioid users for prevention of HIV infection”, The Cochrane database of systematic reviews, 2011.
Gowing, L., Farrell, M.F., Bornemann, R., Sullivan, L.E., Ali, R.: Oral substitution treatment of injecting opioid users for prevention of HIV infection. The Cochrane database of systematic reviews. (2011).
Gowing, Linda, Farrell, Michael F., Bornemann, Reinhard, Sullivan, Lynn E., and Ali, Robert. “Oral substitution treatment of injecting opioid users for prevention of HIV infection”. The Cochrane database of systematic reviews 8 (2011).
This data publication is cited in the following publications:
This publication cites the following data publications:

18 Citations in Europe PMC

Data provided by Europe PubMed Central.

Non-Medical Prescription Opioid Use and Prescription Opioid Use Disorder: A Review.
Tetrault JM, Butner JL., Yale J Biol Med 88(3), 2015
PMID: 26339205
Biomedical HIV Prevention Including Pre-exposure Prophylaxis and Opiate Agonist Therapy for Women Who Inject Drugs: State of Research and Future Directions.
Page K, Tsui J, Maher L, Choopanya K, Vanichseni S, Mock PA, Celum C, Martin M., J. Acquir. Immune Defic. Syndr. 69 Suppl 2(), 2015
PMID: 25978484
Increasing prevalence of HIV infection among first time clients in Italian drug treatment services - is it sexual transmission?
Cruciani M, Wiessing L, Serpelloni G, Genetti B, Andreotti A, Iulia C, Zermiani M, Suligoi B., BMC Infect. Dis. 15(), 2015
PMID: 25925747
Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.
D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, Fiellin DA., JAMA 313(16), 2015
PMID: 25919527
Is the promise of methadone Kenya's solution to managing HIV and addiction? A mixed-method mathematical modelling and qualitative study.
Rhodes T, Guise A, Ndimbii J, Strathdee S, Ngugi E, Platt L, Kurth A, Cleland C, Vickerman P., BMJ Open 5(3), 2015
PMID: 25748417
Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058.
Metzger DS, Donnell D, Celentano DD, Jackson JB, Shao Y, Aramrattana A, Wei L, Fu L, Ma J, Lucas GM, Chawarski M, Ruan Y, Richardson P, Shin K, Chen RY, Sugarman J, Dye BJ, Rose SM, Beauchamp G, Burns DN; HPTN 058 Protocol Team., J. Acquir. Immune Defic. Syndr. 68(5), 2015
PMID: 25564105
Combined prevention for persons who inject drugs in the HIV epidemic in a transitional country: the case of Tallinn, Estonia.
Uuskula A, Des Jarlais DC, Raag M, Pinkerton SD, Feelemyer J., AIDS Care 27(1), 2015
PMID: 25054646
Enhancing motivation within a rapid opioid substitution treatment feasibility RCT: a nested qualitative study.
Ayres R, Ingram J, Rees A, Neale J, Beattie A, Telfer M., Subst Abuse Treat Prev Policy 9(), 2014
PMID: 25407020
The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients.
Edelman EJ, Chantarat T, Caffrey S, Chaudhry A, O'Connor PG, Weiss L, Fiellin DA, Fiellin LE., Drug Alcohol Depend 139(), 2014
PMID: 24726429
Changes in HIV incidence among people who inject drugs in Taiwan following introduction of a harm reduction program: a study of two cohorts.
Huang YF, Yang JY, Nelson KE, Kuo HS, Lew-Ting CY, Yang CH, Chen CH, Chang FY, Liu HR., PLoS Med. 11(4), 2014
PMID: 24714449
A cluster randomized trial of an organizational linkage intervention for offenders with substance use disorders: study protocol.
Friedmann PD, Ducharme LJ, Welsh W, Frisman L, Knight K, Kinlock T, Mitchell SG, Hall E, Urbine T, Gordon M, Abdel-Salam S, O'Connell D, Albizu-Garcia C, Knudsen H, Duval J, Fenster J; Jennifer Pankow for the CJ-DATS MATICCE Workgroup., Health Justice 1(6), 2013
PMID: 25309847
Managing psychiatric comorbidity within versus outside of methadone treatment settings: a randomized and controlled evaluation.
Brooner RK, Kidorf MS, King VL, Peirce J, Neufeld K, Stoller K, Kolodner K., Addiction 108(11), 2013
PMID: 23734943
Mitigating the risk of HIV infection with opioid substitution treatment.
Gowing LR, Hickman M, Degenhardt L., Bull. World Health Organ. 91(2), 2013
PMID: 23554530
Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis.
MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, Degenhardt L, Hickman M., BMJ 345(), 2012
PMID: 23038795
Improving treatment enrollment and re-enrollment rates of syringe exchangers: 12-month outcomes.
Kidorf M, King VL, Gandotra N, Kolodner K, Brooner RK., Drug Alcohol Depend 124(1-2), 2012
PMID: 22209388

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 21833948
PubMed | Europe PMC

Search this title in

Google Scholar